Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Multicenter Phase 1 Study of E7046 in Subjects With Selected Advanced Malignancies

Next Previous
Trial Profile

An Open-Label Multicenter Phase 1 Study of E7046 in Subjects With Selected Advanced Malignancies

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Palupiprant (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Head and neck cancer; Liver cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; First in man
  • Sponsors Eisai Inc

    • Most Recent Events

    • 27 Sep 2022 Results (n=48) of Population pharmacokinetic analysis( from two phase 1 studies NCT02540291 and NCT03152370) to characterize the pharmacokinetic profle of orally administered AN0025 after single and multipledoses in cancer patients presented at the 2022 American College of Clinical Pharmacology Annual Meeting
    • 30 Jul 2018 Status changed from recruiting to discontinued.
    • 12 Sep 2017 Results (n=30) presented at the 42nd European Society for Medical Oncology Congress
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top